TXMD TherapeuticsMD Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving TherapeuticsMD, Inc.

Levi & Korsinsky announces it has commenced an investigation of TherapeuticsMD, Inc. (NYSEMKT: TXMD). On April 10, 2017, TherapeuticsMD announced receipt of a letter from the U.S. Food and Drug Administration stating that its ongoing review of the Company’s New Drug Application (NDA) for TX-004HR has discovered “deficiencies that preclude discussion of labeling and postmarketing requirements/commitments at this time.” Following this news, shares of TherapeuticsMD were down more than 17% on intraday trading on April 10, 2017. To obtain additional information, go to:

http://zlk.9nl.com/therapeuticsmd-txmd

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
10/04/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TherapeuticsMD Inc.

 PRESS RELEASE

TherapeuticsMD Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg ...

BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, announced today that the Company submitted a supplemental New Drug Application (“sNDA”) for BIJUVA (estradiol and progesterone) capsules, 0.5 mg/100 mg, to the U.S. Food and Drug Administration (“FDA”). The Company expects to learn of the acceptance of the sNDA upon receipt of the Filing Review Notification from the FDA, approximately 74 days after submission. If accepted, the Company expects that the review time under the Prescription Drug User Fee Act (PDUFA) will be w...

 PRESS RELEASE

The Sun Sentinel Names TherapeuticsMD, Inc. a Winner of the South Flor...

BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NASDAQ: TXMD), has been awarded a Top Workplaces 2021 honor by The Sun Sentinel. The list is based solely on gathered through a third-party survey administered by employee engagement technology partner , LLC. The anonymous survey uniquely measures 15 culture drivers that are critical to the success of any organization including alignment, execution, and connection. “During this very challenging time, Top Workplaces has proven to be a beacon of light for organizations, as well as a sign of resiliency and strong business performance,” s...

 PRESS RELEASE

TherapeuticsMD Announces First Quarter 2021 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare Company, today reported financial results for the first quarter ended March 31, 2021. “I am pleased with our ongoing execution across the organization, which is in-line with our 2021 operating plan led by ANNOVERA, which performed well in a challenging environment. Our financial performance continues to improve year-over-year. Both menopausal products, IMVEXXY and BIJUVA, had record net revenue per unit. We are also pleased to report that three new ANNOVERA patents were obtained,...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch